This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | MicrobiomeTrials
← Back to trials NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-12-01Est. Completion: 2029-12
Enrollment target: 433 participantsLocations Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States Karmanos Cancer Institute, Detroit, Michigan, United States Washington University School of Medicine, St Louis, Missouri, United States Duke Cancer Center, Durham, North Carolina, United States James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States Scri Oncology Partners, Nashville, Tennessee, United States The University of Texas Md Anderson Cancer Center, Houston, Texas, United States Next Oncology Dallas, Irving, Texas, United States Next Oncology, San Antonio, Texas, United States Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia Southern Highlands Private Hospital, Bowral, New South Wales, Australia Concord Repatriation General Hospital, Concord, New South Wales, Australia Macquarie University, North Ryde, New South Wales, Australia Townsville University Hospital, Douglas, Queensland, Australia Other microbiome trials you might be interested in Advanced Solid Tumor
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary …
Birmingham, United States Est. completion Nov 1, 2028
Non-Small Cell Lung Cancer (NSCLC)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who rece…
Santa Barbara, United States Est. completion Jun 30, 2027
Genesiscare St Andrews, Adelaide, South Australia, Australia
Austin Health, Heidelberg, Victoria, Australia
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Brazil
Hospital Sirio Libanes Brasilia, Brasília, Brazil
Centro de Pesquisas Oncologicas Cepon, Florianópolis, Brazil
Liga Norte Riograndene Contra O Cancer, Natal, Brazil
Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petrópolis, Brazil
Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil
Instituto Nacional de Cancer, Rio de Janeiro, Brazil
Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Brazil
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, São Paulo, Brazil
Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, São Paulo, Brazil
Hospital Israelita Albert Einstein, São Paulo, Brazil
Beijing Cancer Hospital, Beijing, Beijing Municipality, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai Municipality, China
Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, France
Centre Francois Baclesse, Caen, France
Centre Oscar Lambret, Lille, France
Institut Paoli Calmettes, Marseille, France
Institut Curie, Paris, France
Centre Eugene Marquis, Rennes, France
Institut de Cancerologie de Louest, Saint-Herblain, France
Institut Gustave Roussy, Villejuif, France
Nagoya University Hospital, Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Shizuoka Cancer Center, Suntogun, Shizuoka, Japan
Pulau Pinang Hospital, George Town, Malaysia
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Sarawak General Hospital, Kuching, Malaysia
National Cancer Institute (Institut Kanser Negara), Putrajaya, Malaysia
The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Moldova
Harbour Cancer and Wellness, Auckland, New Zealand
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea
Gachon University Gil Medical Center, NamdongGu, Incheon Gwang'Yeogsi, South Korea
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, South Korea
The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi, South Korea
Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi, South Korea
Korea University Anam Hospital, SeongbukGu, Seoul Teugbyeolsi, South Korea
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, South Korea
Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, South Korea
Srinagarind Hospital (Khon Kaen University), Muang, Thailand Phase 1
Recruiting
Advanced Solid Tumor Locally Advanced Solid Tumor Metastatic Solid Tumor Platinum-resistant Ovarian Cancer Post Anti-PD-1 Melanoma 2L+ Cervical Cancer Neoadjuvant Melanoma Neoadjuvant Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Non-Small Cell Lung Cancer Post Anti-PD-(L)1 Small Cell Lung Cancer Third Line or Later (3L+) HER2+ Breast Cancer Second or Third Line (2L/3L) Cervical Cancer Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…
Los Angeles, United States Est. completion Aug 2027